Floatz logo

Gosuranemab

Frontotemporal Dementia

University of California, San Franciscomonoclonal_antibodyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the Frontotemporal Dementia cohort.

Asset / SponsorPhaseRating
Flortaucipir
Mayo Clinic
Phase 4BBB
Fludeoxyglucose
University of Michigan
Phase 4BB
Citalopram
Sunnybrook Health Sciences Centre
Phase 4BB
Pittsburgh Compound B Unlabelled
Mayo Clinic
Phase 4BB
Lemborexant
Nova Scotia Health Authority
Phase 4BB

View all 38 →

Same molecule, other indications

Gosuranemab is also rated in:

Alzheimer diseaseDormant
CCC
Indicative · Phase 2
51 / 100
View asset →
tauopathyDormant
CC
Indicative · Phase 1
43 / 100
View asset →
corticobasal degeneration disorderDormant
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →